Tóm tắt

Objectives: To study the relationship of uric acid with some clinical features in Parkinson's patients treated at the Department of Neurology, Military Hospital 103. Subjects and methods: 99 Parkinson patients regardless of age and sex who were inpatiently treated at the Department of Neurology, Military Hospital 103 and 89 healthy people of the same age. The Parkinson’s patients with uric acid metabolism disorder were excluded, patients’ information was collected according to a consistent medical record. Patients were taken 2 mL of blood to measure the concentration of uric acid. Results: 99 Parkinson’s patients (46.4% was male) had an average onset age of 60.64 ± 10.22; the average duration of illness was 4.03 ± 3.78 years. Patients in the early stage of the disease (Hoehn and Yahr score - H&Y = 1 + 2) accounted for 48.5% and in the late stage of the disease (H&Y = 3 + 4 + 5) explained for 51.5%. The uric acid concentration in the disease group (307.14 ± 81.38) was significantly lower than in the control group (325.88 ± 75.69) µmol/L (p < 0.05). Uric acid levels in the early stage (317.14 ± 71.48) were significantly higher than those in the late stage of the disease (298.14 ± 62.33) (p < 0.05). Uric acid levels in patients treated with a combination of L-dopamine and dopamine agonists (315.45 ± 69.24) were significantly higher than those treated with dopamine agonists alone (305.26 ± 88.37) (p < 0.05). Conclusion: Uric acid levels in Parkinson's patients were lower than in healthy people. Uric acid levels gradually decreased by the progress of disease and was related to drugs used to treat Parkinson's disease. * Keywords: Uric acid; Parkinson’s disease; Clinical features.

Abstract

Objectives: To study the relationship of uric acid with some clinical features in Parkinson's patients treated at the Department of Neurology, Military Hospital 103. Subjects and methods: 99 Parkinson patients regardless of age and sex who were inpatiently treated at the Department of Neurology, Military Hospital 103 and 89 healthy people of the same age. The Parkinson’s patients with uric acid metabolism disorder were excluded, patients’ information was collected according to a consistent medical record. Patients were taken 2 mL of blood to measure the concentration of uric acid. Results: 99 Parkinson’s patients (46.4% was male) had an average onset age of 60.64 ± 10.22; the average duration of illness was 4.03 ± 3.78 years. Patients in the early stage of the disease (Hoehn and Yahr score - H&Y = 1 + 2) accounted for 48.5% and in the late stage of the disease (H&Y = 3 + 4 + 5) explained for 51.5%. The uric acid concentration in the disease group (307.14 ± 81.38) was significantly lower than in the control group (325.88 ± 75.69) µmol/L (p < 0.05). Uric acid levels in the early stage (317.14 ± 71.48) were significantly higher than those in the late stage of the disease (298.14 ± 62.33) (p < 0.05). Uric acid levels in patients treated with a combination of L-dopamine and dopamine agonists (315.45 ± 69.24) were significantly higher than those treated with dopamine agonists alone (305.26 ± 88.37) (p < 0.05). Conclusion: Uric acid levels in Parkinson's patients were lower than in healthy people. Uric acid levels gradually decreased by the progress of disease and was related to drugs used to treat Parkinson's disease. * Keywords: Uric acid; Parkinson’s disease; Clinical features.